Sit Less and Move More program for people with CKD
Treatments studied
Part of Hormones & metabolism, Kidney & urinary, Women’s health & pregnancy clinical trials.
This Phase 2 study tests a program to help people with chronic kidney disease (CKD) sit less and move more, plus a medication (semaglutide) for those who qualify. It may help improve health and day-to-day activity while monitoring safety closely.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have CKD with an eGFR between 20 and under 60
- You are able to do resistance training (strength exercises)
- You can use a compatible smartphone or computer with internet
- You are not pregnant and can give informed consent (or have consent as required)
- You have not used a GLP-1 medicine (like semaglutide) in the last 30 days
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a patient-centered program with virtual support to help people with obesity and advanced kidney disease lose weight and improve their chances of getting a kidney transplant. It uses a type of medication called a GLP-1 receptor agonist, which can help with weight loss.
This study tests whether an oral medication called semaglutide can help people with type 2 diabetes, fatty liver, and kidney problems. It aims to see if it can improve kidney function and liver health.
This study tests whether a weight loss medication (semaglutide) can help manage obesity in people who have had a kidney transplant or are at high risk. It aims to improve health outcomes and prevent further kidney decline.
This trial tests whether combining a GLP-1 medication (a type of diabetes drug that also helps with weight loss) with an exercise program can improve physical function in people with obesity. If you are obese and have trouble with daily activities, this study may help you become more mobile and healthier.
This study tests whether weight loss from a medication can improve how you feel, move, and how well your heart works. It's for people who have both obesity and heart failure with reduced pumping strength.
This study checks whether semaglutide is safe and feasible for people with advanced lung diseases and higher body weight. It may help by testing a structured treatment approach, but it includes several health and safety limits.
Hear when a new Obesity trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.